Business Wire
28 Sept 2026, 21:21 UTC · 1h ago
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
Verdict
Headline takes no side. We score AZN +0.40 across two claims — moderately bullish.
- Expected · AZN
+0.40moderately bullish
−1 bearish0bullish +1More positive than 67% of ticker scores this week




